Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP finds
An AP analysis of Food and Drug Administration data shows that agency staffers have not returned to roughly 2,000 pharmaceutical manufacturing firms to conduct surveillance inspections since before the pandemic.